USO 25152

CA266-0001: An open-label, two arms, randomized, Phase 3 study evaluating the efficacy, safety of BMS‑986545-01 versus durvalumab in participants with locally advanced, unresectable Stage III NSCLC, who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (ROSETTA Lung-201)

Disease Types: Lung Cancer Research

Eligibility Requirements:

- Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
- Participants must have received at least 2 cycles of platinum-based concurrent chemotherapy (a total dose of radiation of at least 54 Gy).
- Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Suffolk (Harbour View)
• Virginia Beach (Princess Anne)
• Williamsburg